Volta Therapeutics creates an automated, closed system cell therapy manufacturing technology that brings GMP suites directly to the clinic. The company provides capacity, automation, and customization through continuous manufacturing devices to facilitate streamlined GMP cell therapy manufacturing.
Kite PharmaKite Pharma is a cell therapy company founded in 2009 as a pioneer in cell therapy research. It researches, develops, manufactures, and commercializes cell therapies, including CAR T-cell therapies, and opened its commercial manufacturing site in El Segundo in 2016. Acquired by Gilead Sciences in 2017, Kite operates as an independent operating company within Gilead.FREDERICK, MD
Autolus TherapeuticsSpun out of University College London in 2014, Autolus Therapeutics develops programmed autologous CAR T-cell therapies for cancer and autoimmune diseases. The company combines T-cell programming with clinical development and a 70,000-square-foot commercial manufacturing facility in Stevenage, UK, and its pipeline includes obe-cel and other investigational therapies. Its long-running collaboration with UCL remains central to moving programs from the laboratory into clinical studies.GAITHERSBURG, MD
Tinkeso Therapeutics, IncFrom its base in Valhalla, Tinkeso Therapeutics develops off-the-shelf, allogeneic Natural Killer T (NKT) cell therapies for cancers and autoimmune disorders. Formerly known as Akeso Therapeutics, the early-stage biotech combines native and engineered NKT programs, including a non-genome-edited CD7 CAR-iNKT therapy aimed at blood cancers and a native type III NKT approach for acute myeloid leukemia. Its proprietary expansion platform is designed to produce at least 100 doses of CAR-modified iNKT cells from a single donor leukopak.VALHALLA, NY
Minaris Advanced TherapiesBorn from the 2025 combination of Minaris Regenerative Medicine and WuXi Advanced Therapies, Minaris Advanced Therapies is a global contract development and manufacturing organization serving developers of cell and gene therapies. Its identity rests on a long technical lineage: more than 25 years in therapy manufacturing, over 40 years in advanced testing, and a history that includes producing the first GMP cell therapy lot in the United States in 2004. The company now supports programs from early development through commercial supply across facilities in North America, Europe and Asia.PHILADELPHIA, PA